PURPOSE: Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. METHODS: Patients received cemiplimab 250 mg (n = 6) or 350 mg (n = 7) every 3 weeks intravenously for up to 108 weeks in Part 1. Tumor responses were assessed by investigators every 9 weeks using the Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: Of 13 patients enrolled, median age was 62 years (range 33-75) and eight patients were female. Median duration of cemiplimab exposure was 13.1 weeks (range 3.0‒113.6). At the time of data cut-off, 11 patients (84.6%) had discontinued treatment (majority due to disease progression: n = 8, 61.5%). The most common treatment-emergent adverse events (TEAEs) of any grade were contact dermatitis, rash, and viral upper respiratory tract infection (each n = 3, 23.1%). Five grade ≥ 3 TEAEs were reported in four patients: autoimmune colitis, dehydration, hyponatremia, hypophosphatemia, and muscular weakness. No dose-limiting toxicities were reported and no TEAEs led to death. Cemiplimab concentrations in serum were consistent with previously reported pharmacokinetic characteristics of cemiplimab. No anti-drug antibodies were detected in serum. Objective response rate [ORR; complete response + partial response (PR)] was 30.8% (four PR) and disease control rate [ORR + stable disease (SD)] was 46.2% (6/13; two SD). CONCLUSION: Cemiplimab exhibited antitumor activity in Japanese patients with advanced malignancies. The safety profile was comparable to those previously reported for cemiplimab and other PD-1 inhibitors. TRIAL REGISTRATION: NCT03233139 at ClinicalTrials.gov.
PURPOSE: Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. METHODS:Patients received cemiplimab 250 mg (n = 6) or 350 mg (n = 7) every 3 weeks intravenously for up to 108 weeks in Part 1. Tumor responses were assessed by investigators every 9 weeks using the Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS: Of 13 patients enrolled, median age was 62 years (range 33-75) and eight patients were female. Median duration of cemiplimab exposure was 13.1 weeks (range 3.0‒113.6). At the time of data cut-off, 11 patients (84.6%) had discontinued treatment (majority due to disease progression: n = 8, 61.5%). The most common treatment-emergent adverse events (TEAEs) of any grade were contact dermatitis, rash, and viral upper respiratory tract infection (each n = 3, 23.1%). Five grade ≥ 3 TEAEs were reported in four patients: autoimmune colitis, dehydration, hyponatremia, hypophosphatemia, and muscular weakness. No dose-limiting toxicities were reported and no TEAEs led to death. Cemiplimab concentrations in serum were consistent with previously reported pharmacokinetic characteristics of cemiplimab. No anti-drug antibodies were detected in serum. Objective response rate [ORR; complete response + partial response (PR)] was 30.8% (four PR) and disease control rate [ORR + stable disease (SD)] was 46.2% (6/13; two SD). CONCLUSION:Cemiplimab exhibited antitumor activity in Japanese patients with advanced malignancies. The safety profile was comparable to those previously reported for cemiplimab and other PD-1 inhibitors. TRIAL REGISTRATION: NCT03233139 at ClinicalTrials.gov.
Entities:
Keywords:
Advanced tumors; Anti–PD-1; Cemiplimab; Immunotherapy; Japanese patients
Authors: Elena Burova; Aynur Hermann; Janelle Waite; Terra Potocky; Venus Lai; Seongwon Hong; Matt Liu; Omaira Allbritton; Amy Woodruff; Qi Wu; Amanda D'Orvilliers; Elena Garnova; Ashique Rafique; William Poueymirou; Joel Martin; Tammy Huang; Dimitris Skokos; Joel Kantrowitz; Jon Popke; Markus Mohrs; Douglas MacDonald; Ella Ioffe; William Olson; Israel Lowy; Andrew Murphy; Gavin Thurston Journal: Mol Cancer Ther Date: 2017-03-06 Impact factor: 6.261
Authors: Amita Patnaik; S Peter Kang; Drew Rasco; Kyriakos P Papadopoulos; Jeroen Elassaiss-Schaap; Muralidhar Beeram; Ronald Drengler; Cong Chen; Lon Smith; Guillermo Espino; Kevin Gergich; Liliana Delgado; Adil Daud; Jill A Lindia; Xiaoyun Nicole Li; Robert H Pierce; Jennifer H Yearley; Dianna Wu; Omar Laterza; Manfred Lehnert; Robert Iannone; Anthony W Tolcher Journal: Clin Cancer Res Date: 2015-05-14 Impact factor: 12.531
Authors: Thomas K Eigentler; Jessica C Hassel; Carola Berking; Jens Aberle; Oliver Bachmann; Viktor Grünwald; Katharina C Kähler; Carmen Loquai; Niels Reinmuth; Martin Steins; Lisa Zimmer; Anna Sendl; Ralf Gutzmer Journal: Cancer Treat Rev Date: 2016-02-18 Impact factor: 12.111
Authors: Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer Journal: N Engl J Med Date: 2016-10-08 Impact factor: 91.245
Authors: M Ahamadi; T Freshwater; M Prohn; C H Li; D P de Alwis; R de Greef; J Elassaiss-Schaap; A Kondic; J A Stone Journal: CPT Pharmacometrics Syst Pharmacol Date: 2016-11-14
Authors: Andrew F Dengler; Rachel Weiss; Tiffany Truong; Susan C Irvin; Nidhi Gadhia; Mohamed Hassanein; Camille Georgaros; Jessica-Ann Taylor; Anne Paccaly; Giane Sumner; Matthew D Andisik; Albert Torri; Michael A Partridge Journal: AAPS J Date: 2021-10-04 Impact factor: 4.009